Topic 022 - technological development and validation of remote measures foruse in clinical trials in individuals with rare diseases
Ended Definitive Contract Awarded
- Contract number
- 75N95022C00040
- Awardee
-
Biosensics LLC UEI C9MRZK4B7K39
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $325,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $325,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Newtonville, MA 02458, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
Biosensics LLC has been awarded a $325,000 firm fixed price definitive contract by the National Institutes of Health's National Center for Advancing Translational Sciences to conduct research and development activities aligned with the agency's goals. Specifically, the contract calls for Technological Development and Validation of Remote Measures for Use in Clinical Trials in Individuals with Rare Diseases, as outlined in NIH and CDC Solicitation A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals. All work will be performed by Biosensics in Newton, Massachusetts over a 10-month period concluding in June 2023. This opportunity is set aside for total small business participation.
Quick answers
Who was awarded contract 75N95022C00040?
75N95022C00040 was awarded to Biosensics LLC by National Institute on Drug Abuse (National Institutes of Health) on September 23, 2022.
How much is contract 75N95022C00040 worth?
The government has obligated $325,000 on 75N95022C00040.
Which agency awarded contract 75N95022C00040?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022C00040, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95022C00040 competed?
The extent of competition for 75N95022C00040 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award